New hope for advanced kidney cancer: combo therapies tested in clinical trial

NCT ID NCT04626518

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated May 06, 2026

Summary

This study is for people with advanced kidney cancer that has gotten worse after initial treatment. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 370 participants will receive experimental treatments, and researchers will monitor side effects and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Asan Medical Center ( Site 3800)

Songpagu, Seoul, 05505, South Korea
Auckland City Hospital ( Site 3700)

Auckland, 1023, New Zealand
Austin Health ( Site 3600)

Melbourne, Victoria, 3084, Australia
Barts Health NHS Trust ( Site 3401)

London, London, City of, EC1A 7BE, United Kingdom
Blacktown Hospital ( Site 3601)

Blacktown, New South Wales, 2148, Australia
Bradfordhill-Clinical Area ( Site 4101)

Santiago, Region M. de Santiago, 8420383, Chile
CIDO SpA-Oncology ( Site 4106)

Temuco, Araucania, 4810148, Chile
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 4201)

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Duke Cancer Institute ( Site 3015)

Durham, North Carolina, 27710, United States
Erasmus Medisch Centrum ( Site 4401)

Rotterdam, South Holland, 3015 GD, Netherlands
FALP-UIDO ( Site 4100)

Santiago, Region M. de Santiago, 7500921, Chile
Gustave Roussy ( Site 3202)

Villejuif, Île-de-France Region, 94800, France
Hadassah Medical Center-Oncology ( Site 3504)

Jerusalem, 9112001, Israel
Henry Ford Health System ( Site 3014)

Detroit, Michigan, 48202, United States
Hospital Universitari Vall d Hebron ( Site 3300)

Barcelona, Catalonia, 08035, Spain
Hospital Universitario Ramon y Cajal ( Site 3301)

Madrid, 28034, Spain
Institut Claudius Regaud ( Site 3200)

Toulouse, Haute-Garonne, 31059, France
Institut De Cancerologie De Lorraine ( Site 3204)

Vandœuvre-lès-Nancy, Ain, 54519, France
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 3203)

Strasbourg, Alsace, 67200, France
James Lind Centro de Investigacion del Cancer ( Site 4108)

Temuco, Araucania, 4800827, Chile
Jewish General Hospital ( Site 3100)

Montreal, Quebec, H3T 1E2, Canada
Laura and Isaac Perlmutter Cancer Center ( Site 3016)

New York, New York, 10016, United States
Leicester Royal Infirmary ( Site 3408)

Leicester, Leicestershire, LE1 5WW, United Kingdom
Memorial Sloan Kettering Cancer Center ( Site 3002)

New York, New York, 10065, United States
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4200)

Warsaw, Masovian Voivodeship, 02-781, Poland
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 4402)

Amsterdam, North Holland, 1066 CX, Netherlands
ONCOCENTRO APYS-ACEREY ( Site 4103)

Viña del Mar, Valparaiso, 2520598, Chile
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 4301)

Budapest, Pest County, 1122, Hungary
Princess Margaret Cancer Centre ( Site 3101)

Toronto, Ontario, M5G 1Z5, Canada
Rabin Medical Center ( Site 3502)

Petah Tikva, 4941492, Israel
Rambam Health Care Campus-Oncology Division ( Site 3500)

Haifa, 3109601, Israel
Royal Brisbane and Women's Hospital ( Site 3603)

Herston, Queensland, 4029, Australia
Royal Preston Hospital ( Site 3406)

Preston, Lancashire, PR2 9HT, United Kingdom
Samsung Medical Center ( Site 3801)

Seoul, 06351, South Korea
Severance Hospital ( Site 3802)

Seoul, 03722, South Korea
Sheba Medical Center - Oncology Division ( Site 3501)

Ramat Gan, 52621, Israel
Sourasky Medical Center ( Site 3503)

Tel Aviv, 6423906, Israel
Southampton General Hospital ( Site 3403)

Southampton, England, SO16 6YD, United Kingdom
St George Hospital ( Site 3602)

Kogarah, New South Wales, 2217, Australia
The Beatson West of Scotland Cancer Centre ( Site 3405)

Glasgow, Glasgow City, G12 0YN, United Kingdom
The Christie NHS Foundation Trust ( Site 3400)

Manchester, M20 4BX, United Kingdom
UPMC Cancer Center/Hillman Cancer Center ( Site 3017)

Pittsburgh, Pennsylvania, 15232, United States
UTSW Medical Center ( Site 3003)

Dallas, Texas, 75390, United States
University of California at San Francisco ( Site 3008)

San Francisco, California, 94158, United States
University of Chicago ( Site 3013)

Chicago, Illinois, 60637, United States
University of Iowa ( Site 3012)

Iowa City, Iowa, 52242, United States
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 4202)

Gdansk, Pomeranian Voivodeship, 80-952, Poland
Vanderbilt University Medical Center ( Site 3004)

Nashville, Tennessee, 37232, United States
Velindre Cancer Centre Hospital ( Site 3407)

Cardiff, Wales, CF14 2TL, United Kingdom
Western General Hospital ( Site 3402)

Edinburgh, Midlothian, EH4 2XU, United Kingdom
Yale-New Haven Hospital-Yale Cancer Center ( Site 3011)

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, RENAL CELL